Publications and communications of Nathalie Esser

Articles accepted in reviewed journal

Esser, N., Hogan, M. F., Templin, A. T., Akter, R., Fountaine, B. S., Castillo, J. J., El-Osta, A., Manathunga, L., Zhyvoloup, A., Raleigh, D. P., Zraika, S., Hull, R. L., & Kahn, S. E. (In press). The Islet Tissue Plasminogen Activator/Plasmin System is Upregulated with Human Islet Amyloid Polypeptide Aggregation and Protects Beta Cells from Aggregation-Induced Toxicity. Diabetologia.

Scheen, A., Luyckx, F., Esser, N., & Paquot, N. (March 2024). Vignette diagnostique de l’étudiant. Ne pas négliger le syndrome métabolique. Revue Médicale de Liège, 79 (3), 191 - 194.

Mukherjee, N., Contreras, C. J., Lin, L., Colglazier, K. A., Mather, E. G., Kalwat, M. A., Esser, N., Kahn, S. E., & Templin, A. T. (11 January 2024). RIPK3 promotes islet amyloid-induced β-cell loss and glucose intolerance in a humanized mouse model of type 2 diabetes. Molecular Metabolism, 80, 101877. doi:10.1016/j.molmet.2024.101877

Esser, N., & Paquot, N. (23 August 2023). Actualisation des recommandations nutritionnelles dans le traitement du diabète de type 2. Revue Médicale Suisse, 19 (838), 1486 - 1490. doi:10.53738/REVMED.2023.19.838.1486

Esser, N., Mongovin, S. M., Mundinger, T. O., Barrow, B. M., & Zraika, S. (10 August 2023). Neprilysin deficiency reduces hepatic gluconeogenesis in high fat-fed mice. Peptides, 168, 171076. doi:10.1016/j.peptides.2023.171076

Esser, N., Mundinger, T. O., Barrow, B. M., & Zraika, S. (13 March 2023). Acute Inhibition of Intestinal Neprilysin Enhances Insulin Secretion via GLP-1 Receptor Signaling in Male Mice. Endocrinology, 164 (5). doi:10.1210/endocr/bqad055

Castillo, J. J., Aplin, A. C., Hackney, D. J., Hogan, M. F., Esser, N., Templin, A. T., Akter, R., Kahn, S. E., Raleigh, D. P., Zraika, S., & Hull, R. L. (October 2022). Islet amyloid polypeptide aggregation exerts cytotoxic and proinflammatory effects on the islet vasculature in mice. Diabetologia, 65 (10), 1687 - 1700. doi:10.1007/s00125-022-05756-9

Esser, N., & PAQUOT, N. (May 2022). Inflammation, obésité et diabète de type 2. Rôle de l’inflammasome NLRP3 et du microbiote intestinal. Revue Médicale de Liège, 77 (5-6), 310-315.

SCHEEN, A., LUYCKX, F., Esser, N., LAMPROYE, A., DELWAIDE, J., & PAQUOT, N. (May 2022). Stéatohépatite non alcoolique (NASH) : un modèle d’inflammation métabolique («métaflammation»). Revue Médicale de Liège, 77 (5-6), 316-322.

Esser, N., Mongovin, S. M., Parilla, J., Barrow, B. M., Mundinger, T. O., Fountaine, B. S., Larmore, M. J., Castillo, J. J., Akter, R., Hull, R. L., & Zraika, S. (01 March 2022). Neprilysin inhibition improves intravenous but not oral glucose-mediated insulin secretion via GLP-1R signaling in mice with β-cell dysfunction. American Journal of Physiology - Endocrinology and Metabolism, 322 (3), 307-E318. doi:10.1152/ajpendo.00234.2021

Esser, N., Schmidt, C., Barrow, B. M., Cronic, L., Hackney, D. J., Mongovin, S. M., Hogan, M. F., Templin, A. T., Castillo, J. J., Hull, R. L., & Zraika, S. (2022). Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice. Frontiers in Endocrinology, 13, 888867. doi:10.3389/fendo.2022.888867

Wilkin, C., Colonval, M., Dehairs, J., Esser, N., Iovino, M., Gianfrancesco, M. A., FADEUR, M., Swinnen, J. V., PAQUOT, N., Piette, J., & Legrand, S. (2021). New insights on the PBMCs phospholipidome in obesity demonstrate modulations associated with insulin resistance and glycemic status. Nutrients. doi:10.3390/nu13103461

Esser, N., & PAQUOT, N. (2021). Intérêt de la combinaison sacubitril/valsartan dans le diabète de type 2. Revue Médicale Suisse, 17, 1418-1422.

Esser, N., Utzschneider, K. M., & Kahn, S. E. (2021). On the causal relationships between hyperinsulinaemia, insulin resistance, obesity and dysglycaemia in type 2 diabetes: Reply to Johnson JD [letter]. Diabetologia, 64 (10), 2345-2347. doi:10.1007/s00125-021-05511-6

Hogan, M. F., Hackney, D. J., Aplin, A. C., Mundinger, T. O., Larmore, M. J., Castillo, J. J., Esser, N., Zraika, S., & Hull, R. L. (2021). SGLT2-i improves markers of islet endothelial cell function in db/db diabetic mice. The Journal of endocrinology, 248 (2), 95-106. doi:10.1530/JOE-20-0354

Kahn, S. E., Chen, Y.-C., Esser, N., Taylor, A. J., van Raalte, D. H., Zraika, S., & Verchere, C. B. (2021). The β Cell in Diabetes: Integrating Biomarkers With Functional Measures. Endocrine Reviews, 42 (5), 528-583. doi:10.1210/endrev/bnab021

Kjeldsen, S. A. S., Hansen, L. H., Esser, N., Mongovin, S., Winther-Sørensen, M., Galsgaard, K. D., Hunt, J. E., Kissow, H., Ceutz, F. R., Terzic, D., Mark, P. D., Plomgaard, P., Goetze, J. P., Goossens, G. H., Blaak, E. E., Deacon, C. F., Rosenkilde, M. M., Zraika, S., Holst, J. J., & Wewer Albrechtsen, N. J. (2021). Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism. Journal of the Endocrine Society, 5 (9), 084. doi:10.1210/jendso/bvab084

Templin, A. T., Schmidt, C., Hogan, M. F., Esser, N., Kitsis, R. N., Hull, R. L., Zraika, S., & Kahn, S. E. (2021). Loss of apoptosis repressor with caspase recruitment domain (ARC) worsens high fat diet-induced hyperglycemia in mice. The Journal of endocrinology, 251 (2), 125-135. doi:10.1530/JOE-20-0612

Esser, N., Utzschneider, K. M., & Kahn, S. E. (2020). Early beta cell dysfunction vs insulin hypersecretion as the primary event in the pathogenesis of dysglycaemia. Diabetologia, 63 (10), 2007-2021. doi:10.1007/s00125-020-05245-x

Esser, N., & Zraika, S. (2020). Neprilysin Inhibitors and Angiotensin(1-7) in COVID-19. The British journal of cardiology, 27 (4), 109-111. doi:10.5837/bjc.2020.031

Templin, A. T., Mellati, M., Meier, D. T., Esser, N., Hogan, M. F., Castillo, J. J., Akter, R., Raleigh, D. P., Zraika, S., Hull, R. L., & Kahn, S. E. (2020). Low concentration IL-1β promotes islet amyloid formation by increasing hIAPP release from humanised mouse islets in vitro. Diabetologia, 63 (11), 2385-2395. doi:10.1007/s00125-020-05232-2

Esser, N., & Zraika, S. (2019). Neprilysin inhibition: a new therapeutic option for type 2 diabetes? Diabetologia, 62 (7), 1113-1122. doi:10.1007/s00125-019-4889-y

Hogan, M. F., Ziemann, M., K N, H., Rodriguez, H., Kaspi, A., Esser, N., Templin, A. T., El-Osta, A., & Kahn, S. E. (2019). RNA-seq-based identification of Star upregulation by islet amyloid formation. Protein engineering, design & selection : PEDS, 32 (2), 67-76. doi:10.1093/protein/gzz022

Templin, A. T., Mellati, M., Soininen, R., Hogan, M. F., Esser, N., Castillo, J. J., Zraika, S., Kahn, S. E., & Hull, R. L. (2019). Loss of perlecan heparan sulfate glycosaminoglycans lowers body weight and decreases islet amyloid deposition in human islet amyloid polypeptide transgenic mice. Protein engineering, design & selection : PEDS, 32 (2), 95-102. doi:10.1093/protein/gzz041

Esser, N., Barrow, B. M., Choung, E., Shen, N. J., & Zraika, S. (2018). Neprilysin inhibition in mouse islets enhances insulin secretion in a GLP-1 receptor dependent manner. Islets, 10 (5), 175-180. doi:10.1080/19382014.2018.1502521

ESSER, N., Paquot, N., & Scheen, A. (2015). Inflammatory markers and cardiometabolic diseases. Acta Clinica Belgica, 70 (3), 193-9. doi:10.1179/2295333715Y.0000000004

Esser, N., Paquot, N., & Scheen, A. (2015). Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opinion on Investigational Drugs, 24 (3), 283-307. doi:10.1517/13543784.2015.974804

Scheen, A., ESSER, N., & Paquot, N. (2015). Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control. Diabetes and Metabolism. doi:10.1016/j.diabet.2015.02.003

Legrand-Poels, S., Esser, N., L'Homme, L., SCHEEN, A., PAQUOT, N., & Piette, J. (2014). Free fatty acids as modulators of the NLRP3 inflammasome in obesity / type 2 diabetes. Biochemical Pharmacology. doi:10.1016/j.bcp.2014.08.013

Esser, N., SCHEEN, A., & PAQUOT, N. (01 April 2014). Metabolically healthy overweight and obesity. Annals of Internal Medicine, 160 (7), 514.

ESSER, N., Legrand-Poels, S., Piette, J., Paquot, N., & Scheen, A. (2014). Inflammasome NLRP3 et graisse viscerale. Revue Médicale de Liège, 69 Spec No, 57-61.

ESSER, N., Legrand, S., Piette, J., SCHEEN, A., & PAQUOT, N. (2014). Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Research and Clinical Practice. doi:10.1016/j.diabres.2014.04.006

ESSER, N., L'Homme, L., DE ROOVER, A., KOHNEN, L., SCHEEN, A., MOUTSCHEN, M., Piette, J., Legrand-Poels, S., & PAQUOT, N. (November 2013). Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia, 56, 2487-2497. doi:10.1007/s00125-013-3023-9

L'Homme, L., Esser, N., Riva, L., Scheen, A., Paquot, N., Piette, J., & Legrand, S. (November 2013). Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes/macrophages. Journal of Lipid Research, 54, 2998-3008. doi:10.1194/jlr.M037861

DE SENY, D., COBRAIVILLE, G., CHARLIER, E., NEUVILLE, S., Esser, N., MALAISE, D., MALAISE, O., Calvo, F., RELIC, B., & MALAISE, M. (2013). Acute-phase serum amyloid a in osteoarthritis: regulatory mechanism and proinflammatory properties. PLoS ONE. doi:10.1371/journal.pone.0066769

DE FLINES, J., RORIVE, M., Esser, N., Paquot, N., Luyckx, F., & SCHEEN, A. (2013). La vignette diagnostique de l'etudiant. Mise au point d'un patient consultant pour obesite. Revue Médicale de Liège, 68 (3), 148-53.

Esser, N., Paquot, N., & SCHEEN, A. (2011). Diabete de type 2 et medicaments anti-inflammatoires: nouvelles perspectives therapeutiques? Revue Médicale Suisse, 7 (306), 1614-8, 1620.

ESSER, N., Paquot, N., & Scheen, A. (2010). "Fitness" versus "fatness": impacts cardio-metaboliques respectifs aux differents ages de la vie. Revue Médicale de Liège, 65 (4), 199-205.

Esser, N., Paquot, N., & Scheen, A. (2010). Aptitude physique versus adiposité : impacts cardio-métaboliques respectifs chez l’enfant/adolescent et chez la personne âgée. Médecine des Maladies Métaboliques, 4, 395-401. doi:10.1016/S1957-2557(10)70083-3

Esser, N., Paquot, N., & Scheen, A. (2010). Aptitude physique versus adiposité : aspects physiopathologiques et impacts cardio-métaboliques chez le sujet adulte non diabétique. Médecine des Maladies Métaboliques, 4, 291-298. doi:10.1016/S1957-2557(10)70062-6

ESSER, N., Paquot, N., & Scheen, A. (March 2009). Sujets « métaboliquement sains », bien qu’obèses. Première partie: diagnostic, physiopathologie et prévalence. Obésité: Revue Francophone pour la Recherche Clinique, la Prévention et la Prise en Charge de l'Obésité, 3, 56-65. doi:10.1007/s11690-009-0170-8

Beck, E., ESSER, N., Paquot, N., & Scheen, A. (2009). Sujets de poids normal «métaboliquement obèses» et sujets obèses «métaboliquement sains». Revue Médicale de la Suisse Romande, 5, 1644-1649.

Esser, N., PAQUOT, N., & SCHEEN, A. (2009). Sujets « métaboliquement sains », bien qu’obèses 2ème partie : pronostic et prise en charge. Obésité: Revue Francophone pour la Recherche Clinique, la Prévention et la Prise en Charge de l'Obésité, 4, 134-141. doi:10.1007/s11690-009-0188-y

ESSER, N., & Scheen, A. (2009). Sujets obèses sans anomalies métaboliques. Revue Médicale de Liège, 64 (3), 148-157.

Articles accepted in conference proceedings

Esser, N. (2023). Gut-Specific Neprilysin Deletion Increases Insulin Secretion in High-Fat–Fed Mice. Diabetes, 72(Supplement_1), 1546.

Esser, N., Hogan, M. F., Templin, A. T., Akter, R., Castillo, J. J., Raleigh, D. P., Zraika, S., Hull, R. L., & Kahn, S. E. (September 2022). Islet macrophage depletion does not prevent amyloid-induced upregulation of tissue plasminogen activator (tPA). Diabetologia, 65 (Suppl 1), 1-1469.

AKTER, R., HOGAN, M. F., Esser, N., CASTILLO, J. J., HULL-MEICHLE, R. L., ZRAIKA, S., & KAHN, S. E. (01 June 2022). Cholesterol Accumulation in Islets Increases Steroidogenic Acute Regulatory (StAR) Protein Expression and Decreases Islet Cell Viability and ß-Cell Function. Diabetes, 71 (Supplement_1), 1457. doi:10.2337/db22-1457-p

HOGAN, M. F., Esser, N., TEMPLIN, A. T., CASTILLO, J. J., AKTER, R., HULL, R. L., KAHN, S. E., & ZRAIKA, S. (01 June 2021). Statin Exposure Increases Star (Steroidogenic Acute Regulatory Protein) Expression in Islets: A Novel Mechanism for ß-Cell Dysfunction and Increased Diabetes Risk? Diabetes, 70 (Supplement_1), 130. doi:10.2337/db21-130-or

Castillo, J. J., Aplin, A., Hogan, M. F., Templin, A. T., Esser, N., Akter, R., & Hull, R. L. (2021). The Proinflammatory but Not Cytotoxic Effect of Aggregated IAPP on Islet Endothelial Cells Requires TLR2/4 Signaling. Diabetes, 70 (Suppl 1), 1238.

Castillo, J. J., Hogan, M. F., Aplin, A., Esser, N., Templin, A. T., Hull, R. L., Zraika, S., & Kahn, S. E. (2020). Hyaluronan produced by inflamed islet endothelial cells contributes to hIAPP aggregation. Diabetes, 69 (Suppl 1), 2043.

Esser, N., Hogan, M. F., Templin, A. T., Castillo, J. J., Raleigh, D., Edgar, J. S., Zraika, S., Hull, R. L., & Kahn, S. E. (2020). Plasmin-mediated cleavage of human islet amyloid polypeptide (hIAPP) protects beta-cells from amyloid-induced toxicity. Diabetes, 69 (Suppl 1), 2039.

Esser, N., Schmidt, C. R., Barrow, B., Cronic, L., Hackney, D. J., Mongovin, S., Hull, R. L., & Zraika, S. (2020). Effect of LCZ696 and its components sacubitril and valsartan on insulin secretion and glucose homeostasis in mice. Diabetes, 69 (Suppl 1), 1797.

Hogan, M. F., Esser, N., Templin, A. T., Castillo, J. J., Zraika, S., Hull, R. L., & Kahn, S. E. (2020). Chronic activation of CREB by islet amyloid increases Star (steroidogenic acute regulatory protein). Diabetes, 69 (Suppl 1), 2040.

Templin, A. T., Schmidt, C. R., Hogan, M. F., Esser, N., Kitsis, R., Hull, R. L., Zraika, S., & Kahn, S. E. (2020). Loss of apoptosis repressor with caspase recruitment domain promotes high-fat diet induced hyperglycemia in vivo. Diabetes, 69 (Suppl 1), 2042.

Esser, N., Hogan, M. F., Aplin, A., Templin, A. T., El-Osta, S., Raleigh, D., Edgar, J. S., Zraika, S., Hull, R. L., & Kahn, S. E. (2019). The tissue plasminogen activator (tPA)/plasmin system reduces amyloid formation by cleaving human islet amyloid polypeptide (hIAPP). Diabetes, 68 (Suppl 1), 2124.

Esser, N., Mundinger, T. O., Barrow, B., Mongovin, S., & Zraika, S. (2019). Acute inhibition of intestinal neprilysin enhances glucose-stimulated insulin secretion in mice. Diabetes, 68 (Suppl 1), 1829.

Hogan, M. F., Esser, N., Templin, A. T., Zraika, S., Hull, R. L., El-Osta, S., & Kahn, S. E. (2019). Increased StAR (steroidogenic acute regulatory protein) is detrimental to ß cells and promotes mitochondrial dysfunction. Diabetes, 68 (Suppl 1), 2125.

Templin, A. T., Mellati, M., Zeman-Meier, D., Hogan, M. F., Esser, N., Zraika, S., Hull, R. L., & Kahn, S. E. (2019). Physiological concentrations of IL-1 beta promote islet amyloid deposition by increasing beta-cell secretion of human islet amyloid polypeptide. Diabetes, 68 (Suppl 1), 2126.

Esser, N., Hogan, M. F., Templin, A. T., Ziemann, M., El-Osta, A., Zraika, S., Hull, R. L., & Kahn, S. E. (2018). Tissue plasminogen activator (tPA) expression is increased by islet amyloid formation in vitro. Diabetes, 67 (Suppl 1), 2107.

Parilla, J. P., Mongovin, S., Barrow, B., Esser, N., & Zraika, S. (2018). Pharmacological neprilysin inhibition improves glucose homeostasis in a mouse model of type 2 diabetes. Diabetes, 67 (Suppl 1), 1825.

Gianfrancesco, M., Dehairs, J., L'Homme, L., Colonval, M., Piette, J., Swinnen, J., Paquot, N., Esser, N., & Legrand, S. (2017). The saturation of membrane phospholipids would be a trigger for K+ efflux and NLRP3 inflammasome activation in human monocytes/macrophages. Diabetologia.

Gianfrancesco, M., Dehairs, J., Bloch, K., L'homme, L., Piette, J., Swinnen, J., Paquot, N., Esser, N., & Legrand, S. (August 2016). Involvement of membrane remodelling induced by fatty acids in the regulation of the NLRP3 inflammasome activity in human macrophages. Diabetologia, 59 (Supplement 1), 291.

Esser, N., L'Homme, L., DE ROOVER, A., KOHNEN, L., SCHEEN, A., MOUTSCHEN, M., Piette, J., Legrand-Poels, S., & PAQUOT, N. (2013). Increased Inflammasome and Caspase-1 Activation in Visceral adipose tissue from Metabolically Unhealthy Obese compared to Metabolically Healthy Obese subjects. Diabetes, (62/suppl.1), 555.

Esser, N., L'Homme, L., DE ROOVER, A., KOHNEN, L., SCHEEN, A., Moutschen, M., Piette, J., Legrand-Poels, S., & PAQUOT, N. (March 2013). Différences d’activité de l’inflammasome NLRP3 entre sujets obèses avec et sans anomalies métaboliques. Diabetes and Metabolism, 39 (suppl 1), 102.

Oral presentations in conferences with scientific selection committee

Esser, N., Mongovin, S., Barrow, B. M., & Zraika, S. (21 March 2024). L’invalidation sélective de la néprilysine dans les entérocytes augmente la sécrétion d’insuline chez les souris sous régime riche en graisses [Paper presentation]. Congrès Annuel de la Société Francophone du Diabète, Toulouse, France.

Posters presentations in conferences with scientific selection committee

Esser, N., Hogan, M. F., Templin, A. T., Akter, R., Castillo, J. J., Zraika, S., Hull, R. L., & Kahn, S. E. (June 2022). Macrophage Depletion Does Not Prevent Tissue Plasminogen Activator (tPA) Upregulation in Islets with Amyloid Deposition [Poster presentation]. Cell Symposium: Translational Immunometabolism, Bâle, Switzerland.

Esser, N., Barrow, B. M., Mundinger, T. O., Parilla, J. H., & Zraika, S. (September 2018). Contribution of islet and intestinal neprilysin in modulating beta-cell function [Poster presentation]. The Islet Biology Workshop at Vanderbilt, Nashville, United States.